X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Edelweiss Financial - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs EDELWEISS FINANCIAL - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

EDELWEISS FINANCIAL 
   Change

Edelweiss is among the larger institutional brokerage firms in India, with a strong domestic investment-banking business. It has a good market share in the institutional broking, and strong presence in derivatives. While its strengths remain in priva... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES EDELWEISS FINANCIAL INDOCO REMEDIES/
EDELWEISS FINANCIAL
 
P/E (TTM) x 43.7 27.3 159.8% View Chart
P/BV x 2.8 6.7 41.1% View Chart
Dividend Yield % 0.8 0.4 204.2%  

Financials

 INDOCO REMEDIES   EDELWEISS FINANCIAL
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
EDELWEISS FINANCIAL
Mar-16
INDOCO REMEDIES/
EDELWEISS FINANCIAL
5-Yr Chart
Click to enlarge
High Rs36073 496.8%   
Low Rs24944 561.0%   
Sales per share (Unadj.) Rs119.064.5 184.4%  
Earnings per share (Unadj.) Rs8.45.1 164.3%  
Cash flow per share (Unadj.) Rs15.26.2 245.7%  
Dividends per share (Unadj.) Rs1.601.25 128.0%  
Dividend yield (eoy) %0.52.1 24.6%  
Book value per share (Unadj.) Rs70.745.1 156.7%  
Shares outstanding (eoy) m92.15814.04 11.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.60.9 282.6%   
Avg P/E ratio x36.411.5 317.2%  
P/CF ratio (eoy) x20.09.4 212.1%  
Price / Book Value ratio x4.31.3 332.6%  
Dividend payout %19.124.6 77.9%   
Avg Mkt Cap Rs m28,08347,601 59.0%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,1678,821 24.6%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,96852,539 20.9%  
Other income Rs m40141 28.1%   
Total revenues Rs m11,00752,681 20.9%   
Gross profit Rs m1,56532,673 4.8%  
Depreciation Rs m633902 70.1%   
Interest Rs m6226,201 0.2%   
Profit before tax Rs m9095,712 15.9%   
Minority Interest Rs m0309 0.0%   
Prior Period Items Rs m0477 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1392,354 5.9%   
Profit after tax Rs m7714,144 18.6%  
Gross profit margin %14.362.2 22.9%  
Effective tax rate %15.341.2 37.0%   
Net profit margin %7.07.9 89.1%  
BALANCE SHEET DATA
Current assets Rs m5,725250,758 2.3%   
Current liabilities Rs m5,454217,115 2.5%   
Net working cap to sales %2.564.0 3.9%  
Current ratio x1.01.2 90.9%  
Inventory Days Days62800 7.8%  
Debtors Days Days7236 199.2%  
Net fixed assets Rs m5,3076,944 76.4%   
Share capital Rs m184814 22.6%   
"Free" reserves Rs m6,33125,223 25.1%   
Net worth Rs m6,51636,728 17.7%   
Long term debt Rs m1,323101,036 1.3%   
Total assets Rs m11,970369,846 3.2%  
Interest coverage x15.61.2 1,284.4%   
Debt to equity ratio x0.22.8 7.4%  
Sales to assets ratio x0.90.1 645.0%   
Return on assets %7.08.2 84.8%  
Return on equity %11.811.3 104.8%  
Return on capital %12.423.7 52.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,507175 2,581.3%   
Fx outflow Rs m1,14139 2,891.8%   
Net fx Rs m3,366135 2,490.6%   
CASH FLOW
From Operations Rs m886-37,621 -2.4%  
From Investments Rs m-1,706-481 354.5%  
From Financial Activity Rs m1,31637,879 3.5%  
Net Cashflow Rs m497-223 -223.1%  

Share Holding

Indian Promoters % 59.2 37.3 158.7%  
Foreign collaborators % 0.0 0.1 -  
Indian inst/Mut Fund % 12.5 0.0 -  
FIIs % 6.0 21.1 28.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 41.5 54.0%  
Shareholders   12,805 134,647 9.5%  
Pledged promoter(s) holding % 0.0 52.2 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   REPCO HOME  TALWALKARS BETTER VAL.  INDIABULLS FIN. SER.  CCL INTERNATIONAL  COX & KINGS  



Today's Market

OPEC Meeting; Upcoming IPOs; IDBI Bank, Emami among Top Stocks in Action Today(Pre-Open)

Indian share markets edged up on Friday with Nifty 50 closing above 10,800-levels, even as broader global markets remained weak.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3%

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jun 22, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS